Show Summary Details
Page of

Stargardt Disease 

Stargardt Disease
Stargardt Disease

Aimee V. Chappelow

and Elias I. Traboulsi

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 January 2022

Autosomal recessive Stargardt disease and fundus flavimaculatus represent a single clinical entity caused by mutation of the ABCA4 gene and accumulation of defective gene product (A2E) at the level of the RPE. The autosomal dominant STGD3 phenotype results when a mutation in the ELOVL4 gene produces a truncated protein that fails to fulfill its normal role in fatty acid synthesis. Although the clinical phenotypes of ABCA4-related Stargardt disease and STGD3 vary widely, the majority of patients have progressively worsening visual acuity from less than 20/40 at diagnosis, yellowish “pisciform” fundus flecks, and a “silent choroid” angiographic sign. Adults with Stargardt disease may have a fundus appearance that can be confused with central areolar dystrophy or with advanced “inverse” RP. Clinical molecular testing is now available and has allowed more precise diagnosis. Ongoing studies involving transgenic mouse models and imminent clinical therapeutic studies hold promise for the development of treatment modalities such as targeted gene therapy and nutritional supplementation.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.